SAB Biotherapeutics (NASDAQ:SABS) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS) in a report published on Monday, Benzinga reports. They currently have a $6.00 price objective on the stock.

A number of other analysts also recently weighed in on the company. Brookline Capital Management assumed coverage on SAB Biotherapeutics in a research report on Friday, June 7th. They set a buy rating and a $8.00 target price for the company. Chardan Capital reissued a buy rating and set a $25.00 price target on shares of SAB Biotherapeutics in a report on Monday.

SAB Biotherapeutics Stock Down 3.9 %

SABS opened at $2.21 on Monday. The business has a fifty day simple moving average of $2.85 and a 200 day simple moving average of $3.94. SAB Biotherapeutics has a 1 year low of $2.16 and a 1 year high of $10.50. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.65 and a current ratio of 5.65.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Thursday, August 8th. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.34. The firm had revenue of $0.26 million during the quarter. SAB Biotherapeutics had a negative return on equity of 109.90% and a negative net margin of 1,531.26%. Equities analysts anticipate that SAB Biotherapeutics will post -4.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

Institutional investors have recently modified their holdings of the business. RTW Investments LP acquired a new position in SAB Biotherapeutics in the 4th quarter worth about $6,310,000. BVF Inc. IL acquired a new position in SAB Biotherapeutics in the 4th quarter worth about $6,310,000. Commodore Capital LP acquired a new position in SAB Biotherapeutics in the 4th quarter worth about $1,259,000. Finally, First PREMIER Bank acquired a new position in SAB Biotherapeutics in the 2nd quarter worth about $60,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.